Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Regulatory
  • Psychedelic therapies ride wave of public favor into FDA hearing
  • Regulatory

Psychedelic therapies ride wave of public favor into FDA hearing

BioSpace

Heading into an FDA hearing on Monday regarding the future of psychedelic treatments, public comments show wide support for further exploring the therapeutic potential of these compounds--to match risi

Neuroscience

Read full story

pharminent September 14, 2026 (Last updated: September 16, 2026)

BioSpace

Heading into an FDA hearing on Monday regarding the future of psychedelic treatments, public comments show wide support for further exploring the therapeutic potential of these compounds–to match risi

Neuroscience

Read full story

Post navigation

Previous: FDA Oncology Chief Sets Out His Agenda — and Narrows the Etcamah Precedent
Next: Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval

Related Stories

  • Regulatory

Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval

pharminent September 14, 2026
  • Regulatory

Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion

pharminent September 10, 2026
  • Regulatory

HHS appoints permanent FDA CBER, CDER heads

pharminent September 10, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.